Rowing Following Breast Cancer Chemotherapy

Description

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

Conditions

Breast Cancer Survivors

Talk to us

Study Overview

On this page

Study Details

Study overview

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

Indoor Rowing as a Novel Exercise Therapy for Cardiovascular Rehabilitation in Middle-Aged and Older Breast Cancer Survivors Following Chemotherapy

Rowing Following Breast Cancer Chemotherapy

Condition
Breast Cancer Survivors
Intervention / Treatment

-

Contacts and Locations

Gainesville

Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida, United States, 32611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * diagnosis of primary invasive non-metastatic breast cancer, stages I-III
  • * female based on biological sex
  • * 40 to 80 years of age
  • * completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation
  • * absence of contraindications to exercise or study participation
  • * study clinician approval
  • * do not meet inclusion criteria
  • * receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation
  • * lymphedema stage ≥ 2 prior to study enrolment
  • * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
  • * consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months

Ages Eligible for Study

40 Years to 80 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Demetra Christou, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

2026-05-31